Kevin Gorman, Neurocrine CEO

Neu­ro­crine plots 2024 fil­ing for rare dis­ease drug af­ter 'solid' PhI­II win

Neu­ro­crine’s lead neu­roen­docrinol­o­gy pro­gram has passed its first Phase III test, set­ting up a po­ten­tial FDA fil­ing in 2024.

The San Diego biotech saw its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.